KURT-SALMON
Kurt Salmon, a global management consulting firm, has announced its collaboration with Bertrand Talbotier, who will contribute his expertise, as a Senior Advisor, to the Life Sciences branch.
Having achieved an Industrial Pharmacy DESS (postgraduate degree), in addition to a Marketing Intelligence Masters at HEC (business school), Bertrand Talbotier has 25 years of industry and consulting experience .
His career began with Sanofi, where he held various roles within the Marketing and General Management departments (Paris, Thailand and Hong Kong), including Vice President of French Marketing. As a member of Sanofi’s management board, he made a significant contribution to the merger of Sanofi and Aventis. Bertrand Talbotier also has experience as an entrepreneur . In 2006, he founded his own consulting firm specializing in health care.
During his career, he has assisted with the creation of strategic alliances between various players in the pharmaceutical and health care industries. Further, Bertrand Talbotier chaired a major American health care nonprofit group, BroadReach Healthcare , whose international scope allowed him to influence health care solutions in multicultural environments in Europe, Asia, Africa and the United States.
Bertrand Talbotier is now bringing his skills to Kurt Salmon, where he will assist in developing and strengthening the firm’s dedicated Life Sciences practice (fine chemicals, pharmaceutical industry, cosmetics industry). Kurt Salmon will benefit from his innovative perspective on issues associated with Market Access, Strategic Marketing, Sales Performance, Strategic Alliances and Digital Transformation.
Confronting strategic concerns in a transitional pharmaceutical sector
Historically, the Life Sciences industries, and especially the pharmaceutical industry, were very prosperous, supported by a focused, lucrative “blockbuster” model. The pharmaceutical industry must now address constant pressures associated with turnover and profits. Increasing regulation, growing competition from bio-similar drugs, and the development of biotechnologies are just a few factors the pharmaceutical industry must take into account.
Companies must now develop new, hybrid strategies to address new obligations, such as diversifying their portfolio of products, adopting an extremely targeted approach, focusing on the needs of patients and all health care players and adapting to the significant challenge posed by emerging economies.
“Joining Kurt Salmon and providing an innovative perspective on the current transition in the sector is an exciting challenge in this pivotal period. Many major players in Life Sciences are questioning their future strategies and believe that in order to overcome these numerous challenges, they must adapt their business model. To stand alongside our clients and partners is a vital responsibility and our role is to guide them along a path which will allow them to accelerate their transformation and support innovation, which now, more than ever, is a pressing requirement,” explains Bertrand Talbotier.
“Kurt Salmon has developed significant expertise in optimizing industrial performance, transforming support functions and corporate operations within the Life Sciences sector. The firm is now growing and assisting companies in the sector with strategic concerns, which include market development, strategic alliances and sales performance,” adds Bernard Desprez, Chief Executive Officer at Kurt Salmon
About Kurt Salmon
Kurt Salmon is a consulting firm that provides transformation services to companies across a variety of industries. Kurt Salmon’s 1,200 employees provide company executives with consulting services and innovative ideas which have a direct and concrete impact on the success of their projects and, specifically, on their transformation projects. Kurt Salmon assists executives when exploring new trajectories for their companies. Our consulting teams work alongside our clients in order to better understand their market expectations, help them discern development factors in their business sector and identify a competitive and differentiated strategy which will allow them to demonstrate their leadership.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150203005283/en/
Contact:
WELLCOM
Sonia El Ouardi /Marianne Felce-Dachez
Press Relations
+33
1 46 34 60 60
se@wellcom.fr
/ mfd@wellcom.fr
or
Kurt
Salmon
Marie-Claire Daunis
Press Relations
+33 4 72 82 52
16
marie-claire.daunis@kurtsalmon.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum